Reported Friday, Oct 2 - 12:01pm EDT (TheFly subscription required to read more.)

Reported Friday, Oct 2 - 10:45am EDT (TheFly subscription required to read more.)

Reported Friday, Oct 2 - 10:05am EDT (TheFly subscription required to read more.)

ImmunityBio reported 94% YoY revenue growth as ANKTIVA commercial sales ramp, sending IBRX up 11%, even as the company burned $187mn in free cash flow.

Reported Wednesday, Sep 30 - 12:02pm EDT (TheFly subscription required to read more.)

Reported Tuesday, Sep 22 - 2:25pm EDT (TheFly subscription required to read more.)

Die ImmunityBio-Aktie notiert am 21.09.2026 vorbörslich bei 8,58 USD und liegt damit 1,18 Prozent über dem Schlusskurs. Die Marktkapitalisierung beträgt 8,987 Mrd. USD.

ImmunityBio's Q2 2026 net product revenue hit a record $50.7 million, up 92% year over year. ANKTIVA, label expansions, cash, dilution and the next catalysts.

Reported Wednesday, Sep 9 - 12:15pm EDT (TheFly subscription required to read more.)

ImmunityBio ($IBRX) grew Q2 product revenue 92% to $50.7M, an eighth straight sequential rise. The ANKTIVA papillary sBLA has a PDUFA date of January 6, 2027.

YouTube video by Martyn Lucas INVESTOR

ImmunityBio investors facing significant losses are given the chance to take legal action with Kessler Topaz. Join now for potential recovery.

ImmunityBio directors collected $3.92M at $7.18-$9.50 before a -175% EPS miss. Whether next week's Anktiva readout can reset the bull case is the question.

We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.

Getting your Trinity Audio player ready... NEW YORK, Aug. 10, 2026 — Investors are watching a diverse group of technology and growth companies Monday as Archer Aviation Inc. (NYSE: ACHR), ImmunityBio ...

Reported Monday, Aug 10 - 9:07am EDT (TheFly subscription required to read more.)

Dr. Kim will work through ImmunityBio’s new executive office on governments, health ministries and global access outside the U.S., supporting partnerships for approved therapies.

Reported Tuesday, Aug 4 - 7:44am EDT (TheFly subscription required to read more.)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially, marking the eighth consecutive quarter of sequential growth for ANKTIVA. First-half 2026 net product revenue reached $94.8 million, up 121% versus the first half of 2025. Total Q2 revenue was $51.2 million.Despite revenue growth, Q2 net loss attributable to common stockholders widened to $230.4 million, and first-half net loss to $863.2 million, mainly from non-cash fair value changes and higher interest expense, R&D, and SG&A. Adjusted net loss improved to $81.0 million in Q2 and $167.3 million for the first half. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled $357.4 million. The company highlighted FDA acceptance of an ANKTIVA sBLA with a January 6, 2027 PDUFA date, new UAE marketing authorization, and a U.S.-exclusive Tokyo-172 BCG supply agreement.